Flaxseed oil-trastuzumab interaction in breast cancer

Food and Chemical Toxicology

Volumn 48, Issue 8-9, 2010, Pages 2223-2226

  Mason, Julie K ^a   Chen, Jianmin ^a   Thompson, Lilian U ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; Drug diet interaction; HER2; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLAXSEED OIL; TRASTUZUMAB; UNCLASSIFIED DRUG; VEGETABLE OIL; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; KI 67 ANTIGEN; LINSEED OIL; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER SIZE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; FOOD INTAKE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LOADING DRUG DOSE; LOW DRUG DOSE; MOUSE; NONHUMAN; ORGAN WEIGHT; RESPIRATORY DISTRESS; WHEEZING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST NEOPLASMS; CHEMISTRY; DIET; DRUG EFFECTS; EATING; FLAX; GENETICS; METABOLISM; NUDE MOUSE; ORGAN SIZE; PATHOLOGY; TOXICITY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BODY WEIGHT; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DIET; EATING; FEMALE; FLAX; HUMANS; KI-67 ANTIGEN; LINSEED OIL; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGAN SIZE; PLANT OILS; RECEPTOR, ERBB-2; ANTIBODIES, MONOCLONAL, HUMANIZED;

MUS;

EID: 77955053927     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2010.05.052     Document Type: Article

References (30)

1. Baselga J. Clinical trials of single-agent trastuzumab (Herceptin). Semin. Oncol. 2000, 5(Suppl. 9):20-26.
2. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson I.C., Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 1996, 14:737-744.
3. Bassett C.M., Rodriguez-Leyva D., Pierce G.N. Experimental and clinical research findings on the cardiovascular benefits of consuming flaxseed. Appl. Physiol. Nutr. Metab. 2009, 34:965-974.
4. Bergman Jungestrom M., Thompson L.U., Dabrosin C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin. Cancer Res. 2007, 13:1061-1067.
5. Boon H.S., Olatunde F., Zick S.M. Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Women's Health 2007, 7:4.
6. Canadian Council on Animal Care, 1984. Guide to the Care and Use of Experimental Animals, vol. 2.
7. Chen J., Stavro P.M., Thompson L.U. Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor. Nutr. Cancer 2002, 43:187-192.
8. Chen J., Hui E., Ip T., Thompson L.U. Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (MCF-7) in nude mice. Clin. Cancer Res. 2004, 10:7703-7711.
9. Chen J., Power K.A., Mann J., Cheng A., Thompson L.U. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by down-regulating the expression of estrogen related gene products and signal transduction pathways. Nutr. Cancer 2007, 58:162-170.
10. Cobleigh M., Vogel C., Tripathy D., Robert N., Scholl S., Fehrenbacher L., Wolter J., Paton V., Shak S., Lieberman G., Slamon D. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999, 17:2639-2648.
11. Cohen L.A., Thompson D.O., Choi K., Karmali R.A., Rose D.P. Dietary fat and mammary cancer. II. Modulation of serum and tumor lipid composition and tumor prostaglandins by different dietary fats: association with tumor incidence patterns. J. Natl. Cancer Inst. 1986, 77:43-51.
12. Crone S.A., Zhao Y.Y., Fan L., Gu Y., Minamisawa S., Liu Y., Peterson K.L., Chen J., Kahn R., Condorelli G., Ross J., Chien K.R., Lee K.F. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 2002, 8:459-465.
13. Ghosh-Choudhury T., Mandal C.C., Woodruff K., StClair P., Fernandes G., Choudhury G.G., Ghosh-Choudhury N. Fish oil targets PTEN to regulate NFkappaB for downregulation of anti-apoptotic genes in breast tumor growth. Breast Cancer Res. Treat. 2009, 118:213-228.
14. Izumi Y., Xu L., di Tomaso E., Fukumura D., Jain R.K. Tumor biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002, 416:279-280.
15. Kuhajda F. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2008, 16:202-208.
16. Ma D.W.L., Seo J., Davidson L.A., Callaway E.S., Fan Y.Y., Lupton J.R., Chapkin R.S. N-3 PUFA alter caveolae lipid composition and resident protein localization in mouse colon. FASEB J. 2004, 18:1040-1042.
17. Menendez J., Ropero S., Mehmi I., Atlas E., Colomer R., Lupu R. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal α-linolenic acid and γ-linolenic acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. Int. J. Oncol. 2004, 24:1369-1383.
18. Menendez J., Vellon L., Mehmi I., Oza B.P., Roper S., Colomer R., Lupu R. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu(erbB2) oncogene overexpression in cancer cells. PNAS 2004, 101:10715-10720.
19. Menendez J., Vazquez-Martin A., Ropero S., Colomer R., Lupu R. HER2 (erbB-2)-targeted effects of the ω-3 polyunsaturated. Fatty acid α-linolenic acid (ALA:18:3n-3) in breast cancer cells: the " fat features" of the " Mediterranean diet" as an " anti-HER2 cocktail" Clin. Transl. Oncol. 2006, 8:812-820.
20. Ravdin P.M., Chamness G.C. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene 1995, 159:19-27.
21. Reeves P.G., Nielsen F.H., Fahey G.C. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J. Nutr. 1993, 123:1939-1951.
22. Saggar J., Chen J., Corey P., Thompson L.U. Dietary flaxseed lignan or oil combined with tamoxifen treatment affects MCF-7 tumor growth through estrogen receptor- and growth factor-signaling pathways. Mol. Nutr. Food Res. 2010, 54:415-425.
23. Schley P., Brindley D., Field C.J. (n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells. J. Nutr. 2007, 137:548-553.
24. Serraino M.R., Thompson L.U., Cunnane S.C. Effect of low level flaxseed supplementation on the fatty acid composition of mammary glands and tumors in rats. Nutr. Res. 1992, 12:767-772.
25. Thompson L.U., Rickard S.E., Orcheson L.J., Seidl M. Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis. Carcinogenesis 1996, 17:1373-1376.
26. Thompson L.U., Chen J., Li T., Strasser-Weippl K., Goss P.E. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin. Cancer Res. 2005, 11:3828-3835.
27. Truan, J., Chen, J.M., Thompson, L.U., 2010. Flaxseed oil reduces the growth of human breast tumors (MCF-7) at high levels of circulating estrogen. Mol. Nutr. Food Res. (Epub ahead of print).
28. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
29. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of Trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:719-726.
30. Wang L., Chen J., Thompson L.U. The inhibitory effect of flaxseed on the growth and metastasis of estrogen receptor negative human breast cancer xenografts is attributed to both its lignan and oil components. Int. J. Cancer 2005, 116:793-797.